

# CENTER FOR DRUG EVALUATION AND RESEARCH

## Approval Package for:

### *APPLICATION NUMBER:*

**212643Orig1s000**

*Trade Name:* N/A

*Generic or Proper Name:* Gallium Ga 68 PSMA-11 Injection

*Sponsor:* University of California San Francisco

*Approval Date:* December 1, 2020

*Indication:* For positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:

- with suspected metastasis who are candidates for initial definitive therapy
- with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level

# CENTER FOR DRUG EVALUATION AND RESEARCH

## 212643Orig1s000

### CONTENTS

|                                                           |
|-----------------------------------------------------------|
| <b>Reviews / Information Included in this NDA Review.</b> |
|-----------------------------------------------------------|

|                                                                                                                                                                                                                                                                    |          |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| <b>Approval Letter</b>                                                                                                                                                                                                                                             | <b>X</b> |
| <b>Other Action Letters</b>                                                                                                                                                                                                                                        |          |
| <b>Labeling</b>                                                                                                                                                                                                                                                    | <b>X</b> |
| <b>REMS</b>                                                                                                                                                                                                                                                        |          |
| <b>Officer/Employee List</b>                                                                                                                                                                                                                                       | <b>X</b> |
| <b>Multidiscipline Review(s)</b> <ul style="list-style-type: none"><li>• Summary Review</li><li>• Office Director</li><li>• Cross Discipline Team Leader</li><li>• Clinical</li><li>• Non-Clinical</li><li>• Statistical</li><li>• Clinical Pharmacology</li></ul> | <b>X</b> |
| <b>Product Quality Review(s)</b>                                                                                                                                                                                                                                   | <b>X</b> |
| <b>Clinical Microbiology / Virology Review(s)</b>                                                                                                                                                                                                                  |          |
| <b>Other Reviews</b>                                                                                                                                                                                                                                               | <b>X</b> |
| <b>Risk Assessment and Risk Mitigation Review(s)</b>                                                                                                                                                                                                               |          |
| <b>Proprietary Name Review(s)</b>                                                                                                                                                                                                                                  |          |
| <b>Administrative/Correspondence Document(s)</b>                                                                                                                                                                                                                   | <b>X</b> |

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**212643Orig1s000**

**APPROVAL LETTER**

NDA 212643

**NDA APPROVAL**

University of California San Francisco  
Attention: Thomas A. Hope, MD  
Associate Professor in Residence  
Department of Radiology and Biomedical Imaging  
Box 0628, 505 Parnassus Avenue  
San Francisco, CA 94143-0628

Dear Dr. Hope:

Please refer to your new drug application (NDA) dated September 6, 2019, received September 6, 2019, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for PSMA-11 Ga 68 Injection.

We acknowledge receipt of your major amendment dated September 1, 2020, which extended the goal date by three months.

This new drug application provides for the use of PSMA-11 Ga 68 Injection indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:

- with suspected metastasis who are candidates for initial definitive therapy.
- with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

We note that your October 30, 2020, submission includes final printed labeling (FPL) for your Prescribing Information. We have not reviewed this FPL. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at

FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling text for the Prescribing Information, as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible via publicly available labeling repositories.

### **CARTON AND CONTAINER LABELING**

We acknowledge your October 26, 2020, submission containing final printed carton and container labeling.

### **DATING PERIOD**

Based on the stability data submitted to date, the expiry dating period for PSMA-11 Ga 68 Injection is 4 hours from the End of Synthesis (EOS) when stored in a lead shielded container at 25°C (77°F); excursions are permitted from 15°C to 30°C (59°F to 86°F). Store Ga 68 PSMA-11 Injection within the original container in radiation shielding.

### **ADVISORY COMMITTEE**

Your application for PSMA-11 Ga 68 Injection was not referred to an FDA advisory committee because the application did not raise significant public health questions on the role of the drug in the diagnosis, cure, mitigation, treatment, or prevention of a disease.

### **PROPRIETARY NAME**

If you intend to have a proprietary name for this product, the name and its use in the labeling must conform to the specifications under 21 CFR 201.10 and 201.15. We recommend that you submit a request for a proposed proprietary name review. (See the guidance for industry *Contents of a Complete Submission for the Evaluation of Proprietary Names*. and *PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2018 through 2022*.)

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study(ies) requirement for this application because necessary studies are impossible or highly impracticable since prostate cancer rarely or never occurs in the pediatric population.

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.<sup>3</sup>

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.<sup>4</sup> Information and Instructions for completing the form can be found at FDA.gov.<sup>5</sup>

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

### **POST APPROVAL FEEDBACK MEETING**

New molecular entities and new biological products qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

---

<sup>3</sup> For the most recent version of a guidance, check the FDA guidance web page at

<https://www.fda.gov/media/128163/download>.

<sup>4</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

<sup>5</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

If you have any questions, call Diane Hanner, Regulatory Project Manager, at (301) 796-4058.

Sincerely,

*{See appended electronic signature page}*

Alex Gorovets, MD  
Deputy Director  
Office of Specialty Medicine  
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
  - o Prescribing Information
- Carton and Container

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

ALEXANDER GOROVETS  
12/01/2020 08:59:19 AM